AI-native TechBio company Cellular Intelligence announced on Monday that it has acquired global rights to a clinical-stage cell therapy programme for Parkinson's disease from Danish pharmaceutical company Novo Nordisk A/S (CPH:NOVO-B) (NYSE:NVO).

Cellular Intelligence says that it intends to apply its proprietary AI platform to accelerate clinical development, manufacturing and the path to commercialisation. Novo Nordisk will make an equity investment in the company, while remaining eligible for future milestones and royalties.

Through this agreement, Cellular Intelligence aims to advance the continued clinical development of the cell therapy Parkinson's programme and deliver a disease-modifying therapy for people living with Parkinson's disease.

The programme covers an allogeneic pluripotent stem cell-derived dopaminergic progenitor therapy, currently in a first-in-human Phase 1/2 clinical trial. It has received FDA Fast Track Designation, as well as IND clearance for further clinical development.